Low Counts With a Big Spleen: Hairy Cell Leukaemia
A blood count comes back low in every line. Haemoglobin, white cells, platelets, all under the mark at once. Someone feels the edge of a spleen below the ribs. Then the marrow is tapped and the needle brings back almost nothing, a dry tap, which reads like a botched procedure and is nothing of the kind. That empty syringe is one of the more specific findings in the whole workup, and using it means holding it beside the counts that have been drifting for a year, which is what Healz's memory does.
This post walks the finding from the top: what hairy cell leukaemia is, which line on the differential count gives it away, why the marrow will not aspirate, which markers and which single mutation separate it from its look-alike, and what actually triggers treatment.

What a count that is low in every line is saying
Hairy cell leukaemia is an indolent, low-grade, B-cell lymphoid malignancy, and it is rare: only 1,200 to 1,300 new cases a year in the United States, per the NCI PDQ health professional summary. It accounts for about 2 percent of new leukaemias, is more frequent in men than in women, and the median age at diagnosis is around 52 to 63 in men and 51 to 59 in women (Current Oncology Reports, 2023).
How it announces itself follows from the low counts. Anaemia brings fatigue and breathlessness. Neutropenia brings active infections. Low platelets bring easy bruising and mucocutaneous bleeding. A massively enlarged spleen brings early satiety and increased abdominal girth (per Naik and Saven, Mayo Clinic Proceedings, 2012). The NCI PDQ health professional summary lists the usual presentation as splenomegaly, varying degrees of leukopenia with occasional leukocytosis, pancytopenia, monocytopenia, and marrow infiltrated by atypical cells with prominent cytoplasmic projections.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Two details matter. About a quarter of patients have no symptoms at presentation (Mayo Clinic Proceedings, 2012), and the 2017 consensus guidelines in Blood note that patients commonly come to attention through an incidental pancytopenia, with the enlarged spleen now less frequent than the historical 90 percent because the disease is caught earlier. The second detail is what is missing: lymphadenopathy is absent, except with multiply recurrent progressive disease (NCI PDQ health professional summary).
An unexplained pancytopenia is a long list before it is a diagnosis, and most of it is not a leukaemia. Our post on low blood counts that never recover covers the marrow-failure end of it.
The line on the differential count almost nobody reads
Monocytopenia is the clue hiding in plain sight. The 2017 consensus guidelines in Blood call it a relatively sensitive and specific manifestation of classic hairy cell leukaemia, and Mayo Clinic Proceedings names absolute monocytopenia among the defining features (2012).
The monocyte count is printed on every full blood count with a differential, often in results filed months ago, where a count near zero sits unread beside the haemoglobin everyone is looking at.
Why the marrow tap came back dry
A bone marrow aspirate is meant to draw up liquid marrow. Here it often does not: the bone marrow is usually fibrotic and is not easily aspirated (NCI PDQ health professional summary). The 2017 consensus guidelines in Blood put it more bluntly: a successful aspirate is often not attainable because of a dry tap, and extensive fibrosis precludes the ability to obtain a cellular aspirate.
The cells infiltrate the marrow and drive a fibrotic reaction, and the fibrosis is what defeats the syringe. Which is why the same guidelines state that a trephine bone marrow biopsy and aspirate are both important: the core of bone shows the infiltration the aspirate could not pull out. A patient told the marrow test failed has been told half of something.
On the film the cells are the ones that named the disease: circulating B cells with cytoplasmic projections, the hairy appearance (NCI PDQ health professional summary). Those projections are suggestive, not conclusive.
The marker list that names it
Flow cytometry makes the case. Alongside the B-cell antigens CD19, CD20 at very high levels, and CD22, the cells coexpress CD11c, CD25 and CD103 (NCI PDQ health professional summary). The 2017 consensus guidelines in Blood add CD123, so that CD19, CD20, CD11c, CD25, CD103 and CD123 coexpressed together confirm the diagnostic features of classic disease, and they list staining for annexin-1 among the tests applied to the biopsy.
One mutation, two diseases, and two classifications that disagree
BRAF V600E is described by the NCI PDQ health professional summary as a hairy cell leukaemia-defining genetic feature that can aid in diagnosis. The 2017 consensus guidelines in Blood state that it is present in the overwhelming majority of patients with classic disease and absent in the variant. Troussard and Maitre, in the Journal of Cellular and Molecular Medicine in 2024, report the mutation in 93 to 100 percent of classic cases and in none of the variant cases they tabulate.
The variant is what classic disease gets confused with. It runs with a raised white cell count, 15 to 50 times 10 to the ninth per litre (NCI PDQ health professional summary). Its markers differ: CD25 is negative in all variant cases at diagnosis, CD103 and CD123 are usually dim or negative, and annexin A1, typically present in classic disease, is absent. It also behaves differently on the same drugs, with the response rate and the duration of response to purine nucleoside analogues inferior to those seen in classic hairy cell leukaemia (Journal of Cellular and Molecular Medicine, 2024).
The naming is unsettled, so it is worth saying which edition you are reading. The 2022 revision of the WHO classification of haematolymphoid tumours eliminated hairy cell leukaemia variant as a provisional category and established a new one, splenic B-cell lymphoma/leukaemia with prominent nucleoli, built to hold variant cases alongside the very rare CD5-negative B-cell prolymphocytic leukaemia. That comes from a 2024 correspondence in Leukemia signed by the hairy cell leukaemia consensus group, which objects that pooling the variant with other rare B-cell malignancies risks losing clinical information about it. The 2022 International Consensus Classification took the other route and kept the name hairy cell leukaemia variant, as a provisional entity inside its splenic B-cell lymphoma/leukaemia, unclassifiable category (Journal of Cellular and Molecular Medicine, 2024; Blood, 2022).
What makes a haematologist start treatment
A diagnosis of hairy cell leukaemia is not by itself an instruction to treat. If the patient is asymptomatic and blood counts are maintained in an acceptable range, therapy may not be needed, per the NCI PDQ health professional summary, which lists the decision factors as cytopenias, especially if symptomatic, increasing splenomegaly, and the presence of other, usually infectious, complications.
The 2017 consensus guidelines in Blood put numbers on the cytopenia trigger: haemoglobin under 11 g/dL, platelet count under 100,000 per microlitre, or absolute neutrophil count under 1,000 per microlitre. Symptomatic splenomegaly may also serve as an indication. The same guidelines advise starting therapy before the counts have fallen to a dangerous level and before an active infection is under way.
Treating on symptoms and burden rather than on a number is the logic our post on a high lymphocyte count and watchful waiting sets out for early chronic lymphocytic leukaemia, but the arithmetic lands somewhere very different here. Only about 10 percent of patients do not need treatment at the time of diagnosis (Current Oncology Reports, 2023).
The treatment classes, named without endorsing one: induction uses a purine nucleoside analogue, either cladribine or pentostatin, which the 2017 consensus guidelines in Blood call equally effective, with the choice down to physician preference or patient convenience. NCI PDQ's health professional summary says cladribine, with or without rituximab, remains the standard of care, while adding that nonchemotherapy options may be preferable for older, frail patients at higher risk of infection. For relapsed and refractory disease the 2017 guidelines record complete remissions with the BRAF inhibitor vemurafenib, the payoff of having tested for the mutation.
Remissions here are long. The 2017 guidelines describe very durable remissions lasting years without additional therapy, and say that at relapse the length of the first remission steers the choice: beyond 60 months, re-treatment with the initial therapy may be considered; beyond 24 months, a purine analogue possibly with an anti-CD20 antibody, or a trial; under 24 months, alternative therapy. Follow-up therefore continues, with periodic physical examinations and peripheral blood counts (Current Oncology Reports, 2023).
How Healz holds the markers, the mutation and a year of counts as one case
The whole question here is which of two similar-looking illnesses you are looking at, and the answer sits in a list of surface markers and a single mutation report, read beside a blood count that has been sliding gently for a year. Those three arrive separately and get filed separately. Healz has memory, so the flow cytometry panel, the BRAF result, the marrow report and every blood count you upload sit in one case: abnormal values stay up front, each finding keeps its date, and the monocyte and platelet lines are followed across months rather than read once and lost.
The rest of the case is in the same chat, not spread over ten apps. Frontier AI works it. As a blood test ai analyzer and an ai lab report reader, Healz reads the differential count, the film description, the marker list and the marrow report together. Healz is equipped with root-cause technology, so it does not stop at the first label on the page: it asks what a rushed appointment skips, cross-checks the case against more than a million rare cases, and drills at the distinction that changes the treatment. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- What does a dry bone marrow tap mean?
It means the aspirate could not draw up liquid marrow. In hairy cell leukaemia that is typical rather than unlucky: the bone marrow is usually fibrotic and is not easily aspirated (NCI PDQ health professional summary), and extensive fibrosis precludes obtaining a cellular aspirate (2017 consensus guidelines in Blood). The trephine core biopsy taken alongside it is what shows the infiltration.
- What blood test findings point to hairy cell leukaemia?
Splenomegaly with varying degrees of leukopenia, pancytopenia and monocytopenia, atypical cells carrying prominent cytoplasmic projections, and lymphadenopathy absent (NCI PDQ health professional summary). Monocytopenia is a relatively sensitive and specific feature of classic disease (2017 consensus guidelines in Blood). Confirmation is by flow cytometry and marrow biopsy.
- Does hairy cell leukaemia need treatment right away?
Not always, but usually. If the patient is asymptomatic and counts are maintained in an acceptable range, therapy may not be needed (NCI PDQ health professional summary). The triggers are haemoglobin under 11 g/dL, platelets under 100,000 per microlitre, an absolute neutrophil count under 1,000 per microlitre, or symptomatic splenomegaly (2017 consensus guidelines in Blood). Around 10 percent of patients do not need treatment at diagnosis (Current Oncology Reports, 2023).
- What is the difference between hairy cell leukaemia and the variant?
The variant lacks BRAF V600E, present in the overwhelming majority of classic cases (2017 consensus guidelines in Blood), and its markers differ, with CD25 negative at diagnosis and annexin A1 absent, and it responds less well and for less time to purine nucleoside analogues (Journal of Cellular and Molecular Medicine, 2024). Naming depends on the edition: the 2022 WHO classification folded it into splenic B-cell lymphoma/leukaemia with prominent nucleoli, while the 2022 International Consensus Classification kept the name hairy cell leukaemia variant as a provisional entity under splenic B-cell lymphoma/leukaemia, unclassifiable.
A dry tap is not a wasted procedure, a low monocyte count is not rounding, and a diagnosis is not an automatic start date. All three read correctly only when the counts, the markers and the mutation report are held as one case.
Written by Healz Team · Filed under Health Insights